LONG-TERM RESULTS FOLLOWING ADJUVANT CHEMOTHERAPY IN PATIENTS WITH CLINICAL STAGE I TESTICULAR NONSEMINOMATOUS MALIGNANT GERM CELL TUMORS WITH HIGH RISK FACTORS
- 1 April 1999
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 161 (4) , 1148-1152
- https://doi.org/10.1016/s0022-5347(01)61615-x
Abstract
Conclusions We recommend adjuvant chemotherapy as an efficient therapeutic alternative to retroperitoneal lymphadenectomy for high risk nonseminomatous germ cell tumor of the testis.Keywords
This publication has 39 references indexed in Scilit:
- Bleomycin in germ cell tumor therapy: not all regimens are created equal.Journal of Clinical Oncology, 1997
- Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parametersZeitschrift für Krebsforschung und Klinische Onkologie, 1996
- Treatment of intratubular germ-cell neoplasia and low-stage testicular cancerCurrent Opinion in Urology, 1995
- Können Risikofaktoren die Strategien im Stadium I des Nicht-Seminoms bestimmen?Aktuelle Urologie, 1995
- Treatment of testicular cancer and the development of secondary malignancies.Journal of Clinical Oncology, 1995
- Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumorsUrology, 1994
- Low Toxicity with Continuous Infusion of High-Dose Bleomycin in Poor Prognostic Testicular CancerAmerican Journal of Clinical Oncology, 1993
- Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular CancerNew England Journal of Medicine, 1987
- HISTOPATHOLOGY IN THE PREDICTION OF RELAPSE OF PATIENTS WITH STAGE I TESTICULAR TERATOMA TREATED BY ORCHIDECTOMY ALONEThe Lancet, 1987